The Suitability of Tience® for Treating Acne Scars (NCT07368764) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
The Suitability of Tience® for Treating Acne Scars
Finland20 participantsStarted 2025-05-01
Plain-language summary
This is an open-label, single-center, split-face, pseudo-randomized clinical trial designed to evaluate the efficacy and safety of a human-derived, cell-free adipose tissue derivative (Tience® ), for treating moderate to severe acne scars. Participants will receive three treatment sessions over a three-month period: on Day 0, Day 30, and Day 90. Treatment will be administered via injections to acne-scarred areas on one side of the face. The untreated side will be treated after the follow-up period. Outcomes will be evaluated over a twelve-month period using investigator clinical assessments, patient self-evaluation and VISIA skin analysis system to monitor changes in scar severity and overall skin quality.
Who can participate
Age range
18 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria: healthy volunteers aged 18-40 years who have at least 3-year- old acne scars on their cheeks.
\-
Exclusion Criteria:
* pregnancy or nursing
* cancer or ongoing cancer treatment
* an active skin disease
* Fitzpatric scale 4-6 skin type
* a strong medication used for treating severe acne (e.g., Isotretinoin)
* active acne or Herpes
* antihistamine medication (if the medication can be paused for 7 days during study visits, participation is possible)
* use of biological medications
* tendency for excessive scar formation
* tendency for urticaria (hives)
* systemic medication affecting immunity
* autoimmune disease
* known disease affecting blood clotting (bleeding or thrombosis tendency) (e.g., von Willebrand disease)
* are allergic to the product being studied or any of its ingredients
* smoke
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Postacne Scarring: A Qualitative Global Scarring Grading System (Goodman and Baron)
Timeframe: Participants are evaluated at four time points: Day 0 (prior to the first treatment), Day 30 (prior to the second treatment), Day 90 (prior to the third treatment), and Day 180 (final evaluation visit)
2
Visia® Gen7 Skin Analysis System
Timeframe: Before first treatment, Day 30 before second treatment, Day 90 before third treatment, and Day 180 evaluation visit.